On June 6, 2017, the U.S. Food and Drug Administration approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Caris Life Sciences®, a leading innovator in molecular science, and ASCO have announced that Caris is one of the first laboratories to have a test report optimized for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study. The TAPUR Study is evaluating efficacy of treatments based on patients’ tumor genetic profiles. This designation indicates that the company’s proprietary Caris Molecular Intelligence® comprehensive genomic profiling plus (CGP+) tumor profiling platform report is optimized to molecularly identify and report genomic alterations specifically for the TAPUR Study.
ASCO and Foundation Medicine have announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s comprehensive genomic profiling (CGP) assays, FoundationOne,® FoundationOne® Heme, and FoundationACT® will receive the new “optimized for TAPUR reporting” designation available to entities that demonstrate reporting of nearly 75% of TAPUR-specific genes in a format that meets criteria established for the TAPUR Study. The TAPUR Study is a first-of its-kind clinical trial designed to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of indications already approved by the Food and Drug Administration.
ASCO congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr. Collins appreciates the critical role that federal research plays in advancing our understanding of how to prevent, diagnose, and treat cancer and other life-threatening diseases, and has worked tirelessly to ensure that the United States remains at the forefront of biomedical innovation.
The American Society of Clinical Oncology strongly supports North Carolina House bill 206, which would address inappropriate cost-sharing burdens for oral anti-cancer drugs for the state’s cancer patients. By passing House bill 206, North Carolina would join forty-three other states and the District of Columbia that have enacted similar oral chemotherapy parity legislation.
A new Care Delivery Review in the Journal of Oncology Practice (JOP) by Blase N. Polite, MD, MPP, chair of ASCO's Government Relations Committee and Christine Bestvina, MD evaluates and summarizes current published research that addresses the need for early and continuous Advanced Care Planning (ACP) in oncology care.
ASCO and Illumina, Inc. today announced a joint contribution of variant interpretations of 6,000 associations of somatic genetic alterations—variants linked to tumors—to the CIViC (Clinical Interpretation of Variants in Cancer) resource, an openly accessible database hosted by Washington University in St. Louis.
ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.
The CancerLinQ Discovery™ Research & Publications Committee – the volunteer committee charged with reviewing and approving research requests utilizing data from CancerLinQ Discovery™ – will begin accepting proposals on October 1, 2017.
CancerLinQ LLC and the National Cancer Institute (NCI) have announced a partnership to facilitate the exchange of information between CancerLinQ® participating oncology practices and NCI’s Surveillance, Epidemiology, and End Results (SEER) program, one of the primary sources of data on cancer incidence and survival in the United States. The partnership aims to put valuable population-level cancer data at oncologists’ fingertips, while also strengthening the nation’s cancer surveillance efforts through a national data sharing collaboration.
CancerLinQ LLC has announced a long-term partnership with the U.S. Food and Drug Administration (FDA) that will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. Real-world data from CancerLinQ® will be used to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means, as well as potentially inform FDA regulatory strategy and decision-making processes.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO®, and the National Comprehensive Cancer Network® (NCCN®) have announced a collaboration to provide a link to the NCCN website for easy access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) within CancerLinQ®. This resource will support CancerLinQ® physicians and provides evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.
Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017.
ASCO has developed a “MACRA decision tree” tool to help oncology practices find precise information on their QPP participation status, and any applicable Merit-Based Incentive Payment System (MIPS) exceptions, based on practice or provider-specific information.
The American Medical Association (AMA) is the largest association of physicians and medical students in the United States. The AMA recognizes ASCO as a national speciality society, offering ASCO the ability to advocate on behalf of the oncology community. The follow ASCO in Action Brief is the first of a series that explores ASCO’s work with the AMA on behalf of the oncology community.